Yayın:
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience

Sadeleştirilmiş öğe sayfası
dc.contributor.authorGülbaş, Zafer
dc.contributor.authorMurat Özbalak
dc.contributor.authorNuri Karadurmuş
dc.contributor.authorSemra Paydaş
dc.contributor.authorAlev Türker
dc.contributor.authorTayfur Toptaş
dc.contributor.authorTülin Tuğlular
dc.contributor.authorFevzi Altuntaş
dc.contributor.authorMerih Kızıl Çakar
dc.contributor.authorMehmet Sönmez
dc.contributor.authorZafer Gülbaş
dc.contributor.authorNazlı Demir
dc.contributor.authorLeylagül Kaynar
dc.contributor.authorRahşan Yıldırım
dc.contributor.authorÌhsan Karadoǧan
dc.contributor.authorMutlu Arat
dc.contributor.authorİrem Kapucu
dc.contributor.authorNevin Alayvaz Aslan
dc.contributor.authorVildan Özkocaman
dc.contributor.authorMehmet Turgut
dc.contributor.authorMeltem Kurt Yüksel
dc.contributor.authorMuhi̇t Özcan
dc.contributor.authorSibel Hacıoğlu
dc.contributor.authorİbrahim Barışta
dc.contributor.authorMetin Demirkaya
dc.contributor.authorGüray Saydam
dc.contributor.authorSelami Koçak Toprak
dc.contributor.authorMehmet Birhan Yılmaz
dc.contributor.authorMehmet Onur Demirkol
dc.contributor.authorBurhan Ferhanoğlu
dc.contributor.orcid0000-0003-1237-8281
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0003-3291-8062
dc.contributor.orcid0000-0003-4642-3693
dc.contributor.orcid0000-0001-5265-8128
dc.contributor.orcid0000-0002-2690-8581
dc.contributor.orcid0000-0001-6872-3780
dc.contributor.orcid0000-0003-0978-0923
dc.contributor.orcid0000-0002-2176-4371
dc.contributor.orcid0000-0002-4709-0627
dc.contributor.orcid0000-0002-9184-6065
dc.contributor.orcid0000-0002-2035-9462
dc.contributor.orcid0000-0002-5717-3936
dc.contributor.orcid0000-0003-2039-8557
dc.contributor.orcid0000-0001-9828-1223
dc.contributor.orcid0000-0003-3292-8519
dc.contributor.orcid0000-0003-0014-7398
dc.contributor.orcid0000-0002-1036-0232
dc.contributor.orcid0000-0003-0369-299X
dc.contributor.orcid0000-0002-1326-1918
dc.contributor.orcid0000-0003-0757-9206
dc.contributor.orcid0000-0002-5733-439X
dc.contributor.orcid0000-0003-2880-0117
dc.contributor.orcid0000-0001-8646-1673
dc.contributor.orcid0000-0001-7717-5827
dc.contributor.orcid0000-0002-8169-8628
dc.contributor.orcid0000-0003-3928-5026
dc.contributor.orcid0000-0002-4257-549X
dc.date.accessioned2025-11-13T09:43:10Z
dc.date.issued2020-06-07
dc.identifier.doihttps://doi.org/10.1007/s00277-020-04077-4
dc.identifier.endpage2576
dc.identifier.issn0939-5555
dc.identifier.issue11
dc.identifier.openalexW4239783357
dc.identifier.startpage2565
dc.identifier.urihttps://hdl.handle.net/11421/1984
dc.identifier.urihttps://doi.org/10.1007/s00277-020-04077-4
dc.identifier.volume99
dc.language.isoen
dc.relation.ispartofAnnals of Hematology
dc.rightsrestrictedAccess
dc.subjectNivolumab
dc.subjectHematology
dc.subjectInternal medicine
dc.subjectMedicine
dc.subjectLymphoma
dc.subjectRefractory (planetary science)
dc.subjectOncology
dc.subjectHodgkin lymphoma
dc.subjectImmunotherapy
dc.subjectCancer
dc.subjectBiology
dc.subject.sdg3
dc.titleNivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5058571002

Dosyalar

Koleksiyonlar

Publications